Ben R. Taylor - 15 Jun 2026 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
17 Jun 2026, 17:07:31 UTC
Prior SEC filing
19 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/Jonathan Golightly, attorney-in-fact

Key filing fact

Ben R. Taylor filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 17 Jun 2026.

Key facts

  • This page summarizes Ben R. Taylor's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 17 Jun 2026, 17:07.

Change

  • Previous filing in this sequence was filed on 19 May 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001712276 Primary reporting owner

Taylor Ben R

Relationship
Chief Financial Officer
Address
41 S. RIO GRANDE STREET, SALT LAKE CITY
Signature
/s/Jonathan Golightly, attorney-in-fact
Signature date
17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXRX transaction

Class A Common Stock

Tax liability

Transaction value
Shares
-5,396
Change %
-0.49%
Price
$3.15*
Shares after
1,101,876
Date
15 Jun 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .